bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.09.29.510057

Subchronic oral toxicity study of Aldicarb sulfoxide in Sprague-Dawley rats

Abstract

Aldicarb sulfoxide is the metabolite of the exceedingly deadly carbamate insecticide Aldicarb. Aldicarb sulfoxide is easily soluble in water and has been identified in groundwater. Moreover, Aldicarb sulfoxide is highly hazardous to mammals. However, the toxicity data of Aldicarb sulfoxide is scarce. Here, the effects of relatively low dosages of exposure to Aldicarb sulfoxide on the blood biochemical, hematological, and histopathological parameters were examined in SD rats. The rats were treated with Aldicarb sulfoxide orally at dosages of 0, 6.3, 18.9, and 56.7 g per kg b.w. daily for 12 weeks. The results revealed that Aldicarb sulfoxide induced significant alterations in liver-related biochemical parameters, glucose level, cholesterol level, and uric acid level. Histopathological testing demonstrated cellular alterations in the liver of 18.9 and 56.7 g/kg BW. Together, our data demonstrated that Aldicarb sulfoxide exposure causes liver injury. Furthermore, the no observed adverse effect level (NOAEL) was less than 6.3 g/kg BW, and the lowest benchmark dose (BMD) value was 0.03 g/kg BW. Accordingly, Aldicarb sulfoxides derived no-effect level (DNEL) was calculated as 0.00035 g/kg BW. Thus, this work is an important reference for supervising Aldicarb sulfoxide in the environment and determining safe exposure limits for Aldicarb sulfoxide.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yongchao, J., Yi, L., Juanjuan, D., Yiting, W., Yu, W., Fan, W., Chao, C., Wensheng, Z.. 2022-09-30. Subchronic oral toxicity study of Aldicarb sulfoxide in Sprague-Dawley rats. https://doi.org/10.1101/2022.09.29.510057

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships

The oxindole scaffold has been the center of several kinase drug discovery programs, some of which have led to approved medicines. A series of two oxindole matched pairs from the literature were identified where TLK2 was a potent off-target kinase. The oxindole as long been considered a promiscuous inhibitor template, but across these 4 specific literature oxindoles TLK2 activity was consistent, while the kinome profile was radically different from narrow to broad spectrum coverage. We synthesized a large series of analogues and through quantitative structure-activity relationship (QSAR) analysis, water mapping of the kinase ATP binding sites, small-molecule x-ray structural analysis and kinome profiling, narrow spectrum, sub-family selective, chemical tool compounds were identified to enable elucidation of TLK2 biology.

pharmacology and toxicology↗